— Medical device maker Abiomed, Inc. (NASDAQ: ABMD) reported net income of $69.2 million or $1.51 per share for the third quarter of 2020, vs. $1.09 per share expected.
— Revenue increased 10% annually to $221.6 million during the three-month period, vs. $226.99 million expected
— US revenue rose 8% to $185.6 million, while overseas revenue moved up 29% to $36 million
— Third-quarter gross margin was 82%, down from 83% reported a year earlier
— Announced initiation of the ST-Elevation Myocardial Infarction Door-to-Unloading Pivotal Randomized Controlled Trial during the quarter
— Expects full-year 2020 revenue to be in the range of $846 million to $877 million, up 10% to 14% respectively
— Confirms full-year 2020 unadjusted operating margin guidance in the range of 28% to 30%
Most Popular
Netflix (NFLX): Four reasons why this leader will not be easy to overthrow
Netflix (NASDAQ: NFLX) has for long been the undisputed king of the streaming space. The streaming industry is seeing massive growth with several new players entering the field. It also
Fastenal (FAST) sees strong post-COVID prospects: Is the stock a buy?
The demand for services that involve minimal human interaction is on the rise as people continue to practice social distancing. Fastenal Co. (NASDAQ: FAST), a market-leading supplier of vending machines,
HEXO Corp. (HEXO) Earnings: 3Q21 Key Numbers
HEXO Corp. (NYSE: HEXO) reported its third-quarter 2021 earnings results today. Net revenue rose 2% year-over-year to CAD22.6 million. Net loss narrowed to CAD20.7 million from a loss of CAD19.5
